Researchers of NANBIOSIS U10 Drug Formulation unit of CIBER-BBN and[...]
Miguel Zea, researcher at GAB Group – Nanbiosis U8 Micro–[...]
Integrated solutions to advanced challenges faced by biomedical researchers in nanomedicine, tissue engineering and regenerative medicine, diagnostic and medical device, that includes design and production of biomaterials and nanomaterials and their nanoconjugates, and the characterization of these bio-/nanomaterials, tissues and medicals devices from a physic-chemical, functional, toxicological and biological point of view up to preclinical validation.Contact us
Due to the current pandemic outbreak of COVID-19, caused by the SARS-CoV-2 virus, knowledge about the virus characteristics and the development of its possible diagnostic, treatment and prophylactic devices and systems are high priority in all research institutions worldwide.
NANBIOSIS assigns high priority to the projects related to the SARS-CoV-2 virus offering preferential access. Some of the NANBIOSIS’s services have been suspended or postponed. However the call is open and the proposals will be processed and services required will be provided as soon as possible.
For that purpose, A “COVID-19 Rapid Access” call has been established, valid through the years 2020-21. Urgent procedure will be applied to review and admission of the proposals.
Customized design and production services of biological molecules for Tissue Engineering, Intelligent Devices, Implants, and specially Therapeutic Nanoconjugates and Biosensors by providing for applications such as:
− Therapeutic agents
− Surfaces functionalization: Tissue engineering/scaffolds & biosensors
Antibodies and Haptens
Custom peptides and post modification
Protein-only nanomaterial platform for biomedical purposes
Supply nanoconjugates for applications in Nanomedicine: therapy, contras agents (MRI) & theranostic)
Micro and nanoencapsulation
Preclinical characterization of nanomedicines including physicochemical properties, in vitro and in vivo biological properties (immunology, toxicology an efficacy with appropriated animal models, at either regulatory (cGLP) or non-regulatory conditionsContact us
Development of prototypes and biosensing devices for diagnostic, production of bioreceptor against identified biomarkers an detection of biomarkers for diagnostic, follow-up and prognostic of diseases by NMR spectroscopies in biofluids and tissues.
Development and validation of biosensor
Quatintifaction of Biomarker by NMR
In vivo validation of contrast agents and development of nanoconjugates as contrast agents for MRI and fluorescence.Contact us
Design and production of scaffolds for tissue engineering
Preclinical validation of biomaterials including surface and mechanical characterization and in vitro and in vivo biological properties with appropriated animal models, at either regulatory (cGLP) or non-regulatory conditions
Surface and mechanical characterization
Adhesion of bateria: biofilms
In vivo Validation of medical devices for determined applications in different animal modelsContact us
Platform Unit 1.
Platform Unit 2.
Platform Unit 3.
Scientists linked to ICTS
Projects since 2008
Services since 2008
Publications since 2008